Questions surrounding Advanced Cell Technology's claim that they found an ethical method for obtaining embryonic stem cells hurt their share price. But they still managed to raise $13 million through two financing deals.
The unsurprising spin from LifeNews:
Despite such accusations, the company's scientists maintain that their August 23 paper in Nature shows it's possible to derive stem cells from a single cell removed from an embryo without damaging it.